Academic gerontology group built a recurring Khavinson reorder line for a 3-year cross-validation programme
A European academic gerontology group running a 3-year cross-validation programme on Khavinson short-peptide bioregulators needed continuity of supply across all eight family members. Forecast-based reservation, harmonised sequence-verification packets, and a Russian-language literature pointer per SKU made Lyochem the recurring supplier for the duration of the programme.
Published April 22, 2026 · Anonymized research-buyer story
Khavinson SKUs qualified
8 + Epitalon
Forecast horizon
12 months (renewed)
Sequence-verification coverage
Every lot
Programme duration
3 years scheduled
Challenge
The group's Principal Investigator was launching a 3-year cross-validation programme on the Khavinson bioregulator framework, aimed at independent replication of the major Russian-school tissue-specific bioregulator findings in a Western academic context. The programme required all eight Khavinson family members at consistent ≥99 % purity with sequence-verification on every lot, plus the kind of literature-pointer support a Western academic group needs when the primary references are Russian-language sources. Most Western catalogue suppliers do not carry the full Khavinson set and the suppliers that do often do not provide sequence verification by LC-MS/MS for the close-mass tetrapeptide family members.
Approach
Lyochem's atelier scoped the recurring-order programme across all eight Khavinson SKUs (Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen plus Epitalon as the cross-listed longevity-category member), reserved synthesis capacity against a 12-month forward forecast, and released each lot with explicit sequence-verification covering the close-mass family members (AEDG / AEDL / AEDP / KED disambiguation). The Khavinson source-literature pointer (Russian-language reference list) was attached to each first-order lot report so the lab's bibliography team had a starting point for the protocol literature review.
Outcome
All eight Khavinson SKUs cleared the lab's QC qualification in the first delivery cycle. The 12-month forecast carried the programme through year one without lead-time complaints, and the reservation has been renewed for year two. The lab's published interim findings have referenced Lyochem as the bulk-active supplier with documented sequence-verification on each lot — a methodology disclosure the gerontology journal flagged as essential for the Khavinson replication context.
“Sequence verification on the AEDG / AEDL / AEDP / KED family was the difference between a replicable study and one a reviewer can question on identity grounds. Lyochem treats the Khavinson catalogue as a defined research set, not a generic peptide line — that was decisive.”